TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02363855
Drug: BAY 1841788(ODM-201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
Study: NCT02218684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01994642
Drug: CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01994642
Drug: Placebo Sterile Otic Suspension
Normalized name: Otocort Sterile Suspension Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619839
Drug: NKTR-181
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
Study: NCT03228771
Drug: PRGF/ATV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin loaded in PRGF fibrin scaffold
Study: NCT03228771
Drug: ATV gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin loaded in methyl cellulose gel
Study: NCT04610047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01091831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
Study: NCT03739710
Drug: GSK4428859A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4428859A/EOS884448 will be administered.
Study: NCT02111330
Drug: PBF-509
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02111330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002781
Drug: boronophenylalanine-fructose complex
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03218384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
Study: NCT00329459
Drug: sumatriptan succinate/naproxen sodium
Normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00329459
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match
Study: NCT00814346
Drug: EGb761®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks for AD patients, 18 months for MC and CNE patients
Study: NCT00814346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet BID
Study: NCT04228445
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01061645
Drug: MOC31-PE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotoxines
Study: NCT01740063
Drug: DAS181-F02 formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01740063
Drug: DAS181-F04 formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01740063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02513238
Drug: Isotonic NaCl
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04608955
Drug: WX-081
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
Study: NCT04608955
Drug: Multi-drug background treatment (MBT)
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Study: NCT02296294
Drug: Elo-mel® (Fresenius Kabi Austria)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
Study: NCT01806454
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00354640
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 milligram tablet PO QD for 14 days
Study: NCT00876616
Drug: Tacrolimus+Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FK506 4mg/d,MMF 1.0g/d
Study: NCT00876616
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CTX 0.75g/m2 BSA
Study: NCT01041313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
Study: NCT01827150
Drug: Redbull, energy drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
Study: NCT03625960
Drug: Trichloroacetic Acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
Study: NCT02289495
Drug: GSK2838232
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Study: NCT02289495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Study: NCT00835276
Drug: ALLEGRA® 180 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 180 mg
Study: NCT01467505
Drug: Immunosuppressant Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
Study: NCT02807623
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Study: NCT02807623
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Study: NCT02221219
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Study: NCT02221219
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
Study: NCT02613871
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01483248
Drug: Conventional therapy plus placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Study: NCT00437346
Drug: Lanzo Melt
Normalized name: Feldene Melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, od, 1/2 h before meal
Study: NCT02116543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00507689
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
Study: NCT02749578
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00031135
Drug: Choline Chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01518634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
Study: NCT01057758
Drug: SIMVASTATIN
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
Study: NCT01057758
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
Study: NCT05242926
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
Study: NCT00779545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Study: NCT00170872
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03861767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
Study: NCT00366938
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01156480
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Study: NCT01156480
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Study: NCT04440267
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT04440267
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT00702468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
Study: NCT03400488
Drug: AZD5718 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
Study: NCT00000376
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00845832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv on days 1 and 15 (Parts 1 and 2)
Study: NCT00888979
Drug: Nicotrol Inhaler
Normalized name: Nicotrol Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
Study: NCT00309088
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02129582
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00429559
Drug: Hycamptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
Study: NCT04408937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for oral administration
Study: NCT03226899
Drug: XOI
Normalized name: TOXOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
Study: NCT03226899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral tablet
Study: NCT03226899
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
Study: NCT01291381
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
Study: NCT00640484
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)
Study: NCT03470675
Drug: Epidural saline + IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline injection in the epidural catheter and in the intravenous catheter
Study: NCT02052219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT01351272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984984
Drug: methylprednisolone PO
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
Study: NCT00984984
Drug: methylprednisolone IV
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
Study: NCT02210806
Drug: Proventil® MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 90 mcg, 1 inhalation
Study: NCT02210806
Drug: Proventil® MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 90 mcg, 2 inhalations
Study: NCT02084485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00657046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules with mannitol substituted for droxidopa
Study: NCT00546624
Drug: MK0777
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01359592
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01359592
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020449
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03881111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study: NCT00623324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match the number of active tablets
Study: NCT03591718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection
Study: NCT01337336
Drug: Anticholinergics
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium; ipratropium alone; or ipratropium + albuterol
Study: NCT02241564
Drug: Switch from calcineurin inhibitor to an mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01285817
Drug: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393494
Drug: Epiduo Topical Product
Normalized name: Epiduo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLD product
Study: NCT03393494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT02528825
Drug: Remifentanil titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
Study: NCT03004365
Drug: C16G2 Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Peptide
Study: NCT03004365
Drug: Placebo Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01305733
Drug: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Study: NCT00373464
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316380
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study: NCT00044694
Drug: Placebo 0.01 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
Study: NCT00044694
Drug: Placebo 0.03 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
Study: NCT00044694
Drug: Placebo 0.04 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
Study: NCT00044694
Drug: AC2993 2.5 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
Study: NCT00044694
Drug: AC2993 5.0 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
Study: NCT00044694
Drug: AC2993 7.5 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
Study: NCT00044694
Drug: AC2993 10.0 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
Study: NCT02174393
Drug: Post-Universal Peel Skin Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening
Study: NCT04091425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 placebo-matching IV infusion
Study: NCT02468297
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
Study: NCT03915340
Drug: Rytmonorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
Study: NCT01503008
Drug: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer